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Abstract 34 
Compared to Human immunodeficiency virus 1 (HIV-1), HIV-2 infection is 35 
characterized by a larger proportion of slow or non-progressors. A better understanding of 36 
HIV-2 pathogenesis should open new therapeutic avenues to establish control of HIV-1 37 
replication in infected patients. Here, we studied the production of CD8
+
 T cells and their 38 
capacity for viral control in HIV-2 controllers from the French ANRS CO5 HIV-2 cohort. HIV-2 39 
controllers display a robust capacity to support long-term renewal of the CD8
+ 
T-cell 40 
compartment by preserving immune resources, including hematopoietic progenitors and 41 
thymic activity, which could contribute to the long-term maintenance of the CD8
+
 T-cell 42 
response and the avoidance of premature immune aging. Our data support the presence of 43 
HIV-2 Gag-specific CD8
+
 T-cells that display an early memory differentiation phenotype and 44 
robust effector potential in HIV-2 controllers. Accordingly, we show for the first time that 45 
HIV-2 controllers possess CD8
+ 
T-cells that show an unusually strong capacity to suppress 46 
HIV-2 infection in autologous CD4
+
 T- cells ex vivo, an ability that likely depends on the 47 
preservation of host immune resources. This effective and durable antiviral response 48 
probably participates in a virtuous circle, during which controlled viral replication permits 49 
the preservation of potent immune functions, thus preventing HIV-2 disease progression. 50 
51 
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Introduction 52 
In the absence of an effective vaccine that prevents the HIV-1 acquisition, the long-53 
term suppression of viral replication in infected individuals remains a major objective to 54 
prevent further disease progression and dissemination. Although progression to AIDS can 55 
now be significantly delayed by effective combinatorial antiretroviral therapy (cART), HIV 56 
remission, which is observed in HIV-1 controllers (HIC1) (1) and rare patients who gain 57 
independence from ART after early initiation (2), remains a priority. Much effort, therefore, 58 
has been given to the identification of immune correlates of natural HIV control in an 59 
attempt to decipher the immunological mechanisms that underlie effective control of HIV-1 60 
replication in the absence of ART. A better understanding of these correlates would provide 61 
insights into therapeutic approaches that would modulate the immune system to mimic the 62 
immune parameters of HIV-1 controllers, ultimately leading to a functional cure of HIV-1 63 
infection.  64 
Although HIV-2 shares the same modes of transmission and intracellular mechanisms 65 
of replication as HIV-1, it provides a unique model of attenuated infection by a human 66 
immunodeficiency virus. Compared to HIV-1 infection, HIV-2 infection is predominantly 67 
characterized by a slower decline of CD4+ T-cells and lower levels of immune activation.(1-68 
3). Whilst HIV-2 infected patients who progress towards disease present similar clinical 69 
manifestations and AIDS severity as those infected with HIV-1, they remain a minority (~15-70 
20% of those infected (4)). Many HIV-2 infected individuals spontaneously control their 71 
infection and remain asymptomatic while maintaining undetectable viral loads, signifying a 72 
high prevalence of HIV-2 controllers (HIC2) (9.1% of HIC2 in the ANRS CO5 HIV-2 cohort (5) 73 
vs 0.22% HIC1 in the ANRS CO4 FHDH (French Hospital Database on HIV)(6)). Deciphering the 74 
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immune correlates of HIV-2 control and contrasting these findings with those from HIV-1 75 
controllers may illuminate the key features of HIV pathogenesis and provide critical 76 
information on what is needed to establish natural control of HIV. 77 
It is well established that CD8
+ 
T-cell mediated immunity is critical in the control of 78 
HIV-1 replication from the earliest days of acute HIV-1 infection. However, the HIV-specific T-79 
cell response declines over time and is often lost in the later phases of chronic infection (7). 80 
Moreover, HIV-1 infected individuals with protracted infection usually demonstrate reduced 81 
thymic output and lower naïve T-cell numbers (8-10). This situation, which is reminiscent of 82 
immune aging, likely accounts for the loss of CD8
+ 
T-cell regenerative capacity over time, and 83 
the failure of the T-cell response to adapt to the emergence of escape variants. Only rare 84 
HIC1 (often possessing specific “protective” HLA-class I alleles (11)), are able to maintain 85 
viremia spontaneously and durably at extremely low levels (12). Furthermore, this level of 86 
control has been associated with their capacity to develop and sustain the production of 87 
HIV-specific CD8
+ 
T-cells that are endowed with the capacity to efficiently suppress HIV-1 88 
infection of autologous CD4
+ 
T-cells (13). 89 
In the present work, we focus on the potential role of cellular immunity as a key 90 
player in controlling HIV-2 infection. Strong Gag-specific CD8
+ 
T-cell responses have been 91 
previously observed in HIV-2 infected patients, and their magnitude was inversely associated 92 
with viremia (14, 15). Of note, these HIV-2 Gag-specific CD8
+ 
T-cells were described as 93 
polyfunctional, although they did not contain high levels of cytolytic markers (16). Persistent 94 
CD8
+ 
T-cell renewal is therefore likely to be essential for maintaining long term immune 95 
efficacy against HIV. We embarked here on the fine characterization of HIV-2-specific CD8
+ 
T-96 
cells in HIC2 from the French ANRS CO5 HIV-2 cohort, with particular focus on the 97 
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production of HIV-specific CD8
+ 
T-cells and their HIV-2 suppressive capacity. We describe for 98 
the first time that CD8
+ 
T-cells from HIC2 demonstrate strong capacity to suppress HIV-2 99 
infection in autologous CD4
+ 
T-cells ex vivo. Importantly, HIC2 retain robust lymphopoiesis in 100 
general and CD8
+ 
T-cell production in particular, suggesting that the marked premature 101 
immune aging phenotype seen in HIV-1 infection is not present in these individuals, which is 102 
likely to be key to the maintenance of a durable and efficient CD8
+
 T-cell response. Overall, 103 
our data suggest that the immune correlates of effective control in HIV-2 infected individuals 104 
may derive from the capacity of the immune system to maintain the potent HIV suppression 105 
capacity that is mediated by CD8
+ 
T-cells. 106 
107 
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Material and Methods 108 
Study subjects 109 
HIV-2 controllers (HIC2) were part of the ANRS CO5 VIH-2 cohort and included in the ANRS 110 
IMMUNOVIR 2 study, which focuses on the study of patients with non-progressive infection. 111 
All patients in the present study had characteristic features of HIV controllers i.e. 112 
asymptomatic treatment naïve individuals, infected for at least 5 years, with a CD4
+
 T cell 113 
count > 400 cells/µl and a viral load < 400 RNA copies/ml.  114 
HIC2 were compared to HIV-1-infected individuals: HIV-1 controllers (HIC1) from the ANRS 115 
CO21 Codex cohort and two groups of HIV-1 viremic individuals (one with CD4
+
 T cell count 116 
below 200 cells/ml and another with CD4
+
 T cell count above 500 cells/ml) from the Pitié 117 
Salpêtrière Hospital (France). Mononuclear cells were isolated over a Lymphoprep gradient 118 
and then either used directly or cryopreserved. PBMC from uninfected healthy adults from 119 
the French Blood Bank (Etablissement Français du Sang) were also analyzed. A summary of 120 
clinical attributes of the patients studied is displayed in Table II. 121 
All participants gave their written informed consent. The study was approved by the 122 
institutional ethics committee (i.e. Comité de Protection des Personnes of Ile de France XI). 123 
 124 
Flow cytometry and reagents 125 
In order to generate tetramers, immunodominant HIV-2 epitopes were identified by 126 
screening HIV-2 p27 overlapping peptides in IFNγ elispot assays using HLA typed HIV-2 127 
infected patient PBMCs, going on to define the optimal epitope sequences and length (15). 128 
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HLA-B*5301 p27 TPYDINQML (TL9) and p27 DRFYKSLRA (DA9) tetramers were synthesized as 129 
previously described (17). PBMC were stained with pre-titrated concentrations of 130 
pentamer/tetramer (conjugated to PE) followed by a panel of antibodies as previously 131 
described (18). Directly conjugated and unconjugated antibodies were obtained from the 132 
following vendors: BD Biosciences (BD Biosciences): CD34 (PE), lineage cocktail (CD3, CD14, 133 
CD16, CD19, CD20, CD56 / FITC), CD3 (PerCP-Cyanine 5.5] or Alexa Fluor 700), CD45RA 134 
(FITC), CCR7 (PE-Cyanine 7), CD107α (PE-Cyanine 5), IFNγ (Alexa Fluor 700), and TNFα (PE-135 
Cyanine 7); Beckman Coulter (Beckman Coulter): CD28 (PE-TexasRed), CD45RA (PE-136 
TexasRed); Caltag (Thermo Fisher): CD8 (Alexa Fluor 405), granzyme B (PE-TexasRed); R&D 137 
Systems (R&D Systems Europe): MIP-1β (FITC); BioLegend (Ozyme): CD127 (BV-650), CD27 138 
(Alexa Fluor 700). Cell surface marker stainings were performed using standard 139 
methodologies. CD34+ cell phenotyping was performed on enriched populations. The 140 
immunomagnetic enrichment of CD34+ cells was carried out on PBMCs using MACS 141 
technology, according to the provider’s recommendations (Miltenyi Biotech). Stainings were 142 
analyzed on an LSR Fortessa flow cytometer (BD Biosciences) and data analyzed using FlowJo 143 
v8.2 (FlowJo, LLC) and DIVA (BD Biosciences) softwares. 144 
 145 
Intracellular cytokine staining assay 146 
Purified PBMC were thawed and rested overnight at 37ºC in complete RPMI media (RPMI 147 
1640 supplemented with 10% heat-inactivated fetal calf serum, L-glutamine and antibiotics); 148 
viability was then examined by trypan blue exclusion (typically ≥ 70% viable). For 149 
stimulation, cells were then incubated in the presence of 15-mer overlapping peptides 150 
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covering the HIV-2 p27 protein (10 µM) or an overlapping peptide pool encompassing clade 151 
B HIV-1 Gag (2 µg/ml). p27 stimulated cells were incubated in the presence of anti-CD107α 152 
antibodies for 1h at 37 °C in a 5% CO2 incubator, followed by an additional 5h in the 153 
presence of the secretion inhibitors monensin (2.5 µg/mL; Sigma-Aldrich) and Brefeldin A (5 154 
µg/mL; Sigma-Aldrich). BD Cytofix/Cytoperm™ (BD Biosciences) was used for 155 
permeabilization of the cells prior to staining for intracellular markers. 156 
 157 
In vitro HIV-2 suppression assay 158 
To assess the capacity of CD8
+ 
T-cells to suppress HIV-2 infection of autologous CD4
+ 
T-cells 159 
in vitro, we adapted our previously published HIV-1 suppression assay (19). Briefly, PBMC 160 
were isolated from peripheral blood by density centrifugation. CD4
+ 
and CD8
+ 
T-cells were 161 
then isolated by, respectively, positive and negative magnetic-bead sorting (STEMCELL 162 
Technologies). CD4
+ 
T-cells were activated in complete RPMI media supplemented with 163 
phytohemagglutinin (1 µg/ml) and interleukin-2 (IL-2) (100 IU/ml) for 3 days. CD8
+ 
T-cells 164 
were cultured in non-supplemented culture media. Activated CD4
+ 
T-cells were infected with 165 
HIV-2 SBL (20) using a spinoculation protocol (21) and cultured alone or with autologous 166 
CD8
+ 
T-cells at a 1:1 ratio during 14 days in IL-2 (100 IU/ml) supplemented culture media. 167 
Viral replication was measured by p27 production in culture supernatants every 3-4 days as 168 
determined by enzyme-linked immunosorbent assay (Gentaur). The capacity of CD8
+ 
T-cells 169 
to suppress HIV infection was calculated at the peak of viral replication as the log decrease in 170 
p27 production when superinfected CD4
+ 
T-cells were cultured in the presence of CD8
+ 
T-171 
cells (log[p27 in CD4 T-cell culture/p27 in CD8:CD4 1:1 co-cultures]). 172 
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 173 
TREC quantification  174 
Thymic function was estimated by quantification of signal joint T-cell reception excision 175 
circles (sjTREC) as previously described (22). Briefly, PBMC lysates were subjected to 176 
multiplex polymerase chain reaction (PCR) for 22 cycles using sjTREC and CD3γ chain outer 177 
primer pairs. Each of the amplicons was then quantified using Light Cycler technology (Roche 178 
Diagnostics), performed on 1/100
th
 of the initial PCR, in independent experiments, but on 179 
the same first-round, serially diluted standard curve. This highly sensitive, nested 180 
quantitative PCR assay allows detecting one copy of sjTREC in 10
5
 cells. The sjTRECs were 181 
quantified in triplicate. 182 
 183 
Statistical analysis 184 
Statistical analyses were performed using Prism software (GraphPad). Non-parametric tests 185 
of significance were performed throughout all analyses, using Kruskal-Wallis and Mann-186 
Whitney testing for intergroup comparisons and Spearman rank test to determine 187 
correlations. P values >0.05 were considered not significant. 188 
189 
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Results 190 
HIV-2-positive population characteristics 191 
We studied 20 HIV-2-positive individuals with controlled viremia in the absence of cART. The 192 
detailed characteristics of the patients are reported in Table I. The proportion of female 193 
patients was 60% (n=12); the median age was 49 (Interquartile range (IQR): 42 - 52). At 194 
inclusion, the median time since HIV-2 infection diagnosis was 13.6 years (IQR: 9.7 - 19.3) 195 
and the median CD4
+
 T-cell counts were 893 cells/µl of blood (IQR: 707 - 1170 cells/µl). Two 196 
individuals had detectable, albeit low, HIV-2 viral load (54 and 117 RNA copies/ml). Three 197 
individuals were born in France, 1 in Colombia and 16 in west-African countries (Table I). 198 
Only two of the HIV-2 infected patients studied carried the “HIV-1 protective” B*57 allele 199 
and just one the B*27 allele. The most common class I HLA allele was C*04, which was 200 
carried by nine individuals (45%), of whom five were homozygotes (Table I). All five 201 
C*04/C*04 individuals were born in Ivory Coast. C*04 is a relatively common gene in France 202 
and West Africa. Overall, 11 (55%) individuals expressed homozygous alleles, suggesting that 203 
these individuals came from bottleneck populations with limited genetic diversity. 204 
 205 
HIV-2 controllers show preserved CD8
+ 
T-cell production capacities 206 
We previously showed that exhaustion of lymphopoiesis is a major correlate of 207 
disease progression in HIV-1 infection (9, 23). Our analyses highlighted a marked decline of 208 
primary immune resources in HIV-1 progressors, including CD34
+ 
hematopoietic progenitor 209 
cells (HPC) and naïve CD4
+ 
and CD8
+ 
T-cell numbers. These alterations, which are the 210 
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hallmark features of advanced immune aging, were not observed in HIC1. We therefore 211 
performed similar analyses in HIC2, directly analyzing the frequency and phenotype of CD34
+ 
212 
hematopoietic progenitor cells (Fig. 1A, 1B), as well as the frequency of naïve CD8
+ 
T-cells 213 
from blood (Fig. 1C). The frequency of circulating HPCs (CD34
+
Lin
-
) in HIC2 was high 214 
compared to levels found in untreated HIV-1 infected patients with low CD4
+
 T-cell counts, 215 
and equivalent to those observed in HIC1 (Fig. 1A). In a similar manner, HIC2 displayed a high 216 
proportion of lymphoid precursor progenitor cells that were identified by the CD117
-
217 
CD45RA
+
 phenotype
 
among CD34
+ 
cells (Fig. 1B). Moreover, we found high levels of naïve 218 
lymphocytes within the CD8
+ 
T-cell compartment of these individuals (Fig. 1C). Our results 219 
demonstrate the maintenance of effective lymphopoiesis in HIV-2 infection, which is likely to 220 
be linked with a capacity to sustain the long-term production of naïve CD8
+ 
T-cells. 221 
In HIV-1 infection, the progressive decrease in naïve T-cell proportions in HIV-infected 222 
adults likely results from the antigen-driven maturation of these cells in the absence of 223 
adequate T-cell renewal capacity due to the declining thymic output of new cells (8, 10, 24). 224 
We and others previously reported that thymic function is preserved in HIV-2-infected 225 
individuals with low viral load (25). It was also recently shown that HIV-2 infection in 226 
thymocytes is impaired (26, 27), which may contribute to the maintenance of high CD4
+ 
T-227 
cell counts in HIV-2 infected patients. Here, we measured signal joint T-cell receptor (sjTCR) 228 
excision circles (TREC) levels in total PBMCs to estimate thymic function in HIC2. Naïve CD8
+ 
229 
T-cell counts directly correlated with the amount of sjTREC/ml (Fig. 1D), suggesting that the 230 
maintenance of these cells was related to sustained thymic activity. This is in line with the 231 
correlation between naïve CD8
+
 and naïve CD4
+
 T-cell counts in blood taken from the same 232 
individuals (Supplementary Fig. 1).  233 
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In addition, we assessed the levels of recent thymic emigrants using CD31 expression 234 
(28), which primarily provides information on the thymic history of naïve CD4
+ 
T-cells. In line 235 
with the TREC data, a strong correlation was observed between the frequency of recent 236 
thymic emigrants (i.e. CD31
+
 naïve CD4
+ 
T-cells) and the naïve CD8
+ 
and
 
CD4
+
 T-cell counts 237 
(Fig. 1E and Supplementary Fig. 1). Taken together, these data support the maintenance of a 238 
robust lymphopoietic capacity and thymic output in HIC2 and signifies robust preservation of 239 
the naïve CD8
+ 
T-cell compartment. The latter is central to the mounting of de novo 240 
responses, as recently shown in elderly subjects (29) and old vaccinated primates (30), and 241 
the ability to sustain effective T-cell responses against a virus with high evolutionary rates, as 242 
is the case with HIV. 243 
 244 
HIV-2 Gag-specific CD8
+ 
T-cells display early memory differentiation and robust effector 245 
potential 246 
We next performed a comprehensive characterization of HIV-2-specific CD8
+ 
T-cell 247 
responses. Since the IFNγ response of Gag-specific CD8
+ 
T-cells was found to correlate 248 
inversely with viremia In HIV-2 infected individuals, suggesting an important role of these 249 
cells in controlling HIV-2 infection (15), we decided to focus on phenotyping CD8
+ 
T-cells that 250 
were specific for p27, which is the major component of HIV-2 Gag. To assess the overall 251 
magnitude of HIV-2 Gag-specific CD8
+ 
T-cells in our patients, we performed intracellular IFNγ 252 
staining on CD8
+ 
T-cells from PBMCs that were stimulated with 15 mer overlapping peptides 253 
that spanned the proteome of the HIV-2 p27 protein. Robust p27-specific CD8
+ 
T-cell 254 
responses were detected in most patients (Fig. 2A). These responses were of similar 255 
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magnitude to those observed in HIC1, although a direct comparison cannot be made, 256 
considering that a different antigen would be used to stimulate HIV-1-specific responses. 257 
These cells also exhibited other effector functions, as revealed by co-staining for TNFα, MIP-258 
1β and CD107α (Supplementary Fig. 2), highlighting a polyfunctional profile that has been 259 
previously described (31). We furthered our investigation by using recombinant MHC class I-260 
peptide tetrameric complexes, which more precisely capture the memory differentiation 261 
phenotype of p27-specific CD8
+ 
T-cells (Fig. 2B). We analyzed in particular CD8
+ 
T-cells that 262 
were restricted by HLA-B*5301, since B*53 was the most common allele in our group of 263 
patients. We were able to generate HLA-B*5301 tetramers with the immunodominant p27 264 
epitope TPYDINQML (TL9). All of the seven HLA-B*53 patients tested positive for TL9-specific 265 
CD8
+ 
T-cells. We also detected HLA-B*1401 restricted p27 DA9 (DRFYKSLRA)-specific CD8
+ 
T-266 
cells in two out of two HLA-B*14 patients. 267 
The differentiation phenotype of HIV-2-specific CD8
+ 
T-cells was assessed based on 268 
the surface expression of the receptors CD27, CD28, CCR7, CD45RA and CD127 (Fig. 2C), and 269 
compared to the phenotype of HLA-B*2705 restricted p24 KK10-specific CD8
+ 
T-cells, the 270 
latter selected as the prototype of primary effector cells in HIV-1 infection (18, 32). Overall, 271 
both groups of HIV-specific CD8
+ 
T-cells displayed similar phenotypes, being mainly CD27
+
 272 
CCR7
-
 CD127
-
, with slight but noticeable differences. For example, HIV-2-specific CD8
+ 
T-cells 273 
trended towards higher CD45RA expression. In HIV-1 infected patients, CD45RA expression 274 
was the hallmark of a rare population of resting cells that resemble long-lived memory cells 275 
and were particularly noticeable shortly after viral replication was curtailed by cART (33). 276 
Furthermore, the expression of CD28 was significantly higher on HIV-2-specific CD8
+ 
T-cells 277 
(Fig. 2D), in line with previous observations made with HLA-B*3501 restricted p27 278 
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NPVPVGNIY (NY9)-specific CD8
+ 
T-cells (34). This indicates that HIV-2-specific CD8
+ 
T-cells are 279 
in general less differentiated (35, 36), displaying an even younger phenotype than highly 280 
effective HIV-1-specific CD8
+ 
T-cells. Accordingly, HIV-2 specific CD8
+ 
T-cells are likely to 281 
retain proliferative potential, as previously suggested (34). Nevertheless, despite their early 282 
memory differentiation state, HIV-2-specific CD8
+ 
T-cells express high levels of the 283 
transcription factors T-BET and EOMES (Supplementary Fig. 3), which are key regulators of 284 
memory differentiation and the acquisition of effector functions (37). In accordance with the 285 
expression of these transcription factors, HIV-2-specific CD8
+ 
T-cells possessed high 286 
intracellular levels of granzyme B, at least relative to what is seen in effective HIV-1-specific 287 
CD8
+ 
T-cells (Fig. 2D). Taken together, these data support the presence of robust Gag-specific 288 
CD8
+ 
T-cell responses in HIC2. These cells are characterized by an early or young 289 
differentiation phenotype and display strong effector potential. 290 
 291 
Unstimulated CD8
+ 
T-cells from HIV-2 controllers suppress HIV-2 infection ex vivo 292 
Lastly, we aimed to show that this strong phenotypic functional potential translated 293 
into an effective capacity of these cells to suppress HIV-2 infection. We previously showed 294 
that HIC1 often possess HIV-specific CD8
+ 
T-cells with a striking capacity to suppress infection 295 
by killing HIV-infected autologous CD4
+ 
T-cells (38, 39). This capacity was not found in cART 296 
treated or untreated viremic HIV-1 patients, either during the acute or chronic phase of 297 
infection (38-41). HIV-1 suppression assays provide the most robust method to distinguish 298 
between the functional capacities of CD8
+ 
T-cells from HIV-1 controllers and non-controllers 299 
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(40, 42, 43). We thus sought to adapt this in vitro assay to the study of HIV-2 using an SBL 300 
virus strain (20), with supernatant p27 concentration as a read-out. 301 
We found that CD8
+ 
T-cells from HIC2 have a strong capacity ex vivo to suppress HIV-302 
2 infection of autologous CD4
+ 
T-cells (Fig. 3A), with a median reduction in p27 production of 303 
2.7 logs [IQR: 1.3-3.3]) (Fig. 3B). The viral suppressive capacity shown by the CD8
+ 
T-cells 304 
from HIC2 was remarkably high, comparable to the levels observed with cells from HIC1 305 
from the ANRS CO21 cohort (Fig. 3B) or even among our previous studies (38, 39) . Similarly 306 
to what we found in HIV-1 controllers (39), the capacity of CD8
+ 
T-cells from HIV-2 307 
controllers to suppress infection was relatively stable over time (Fig. 3C). There was however 308 
some heterogeneity in HIV-2 suppressive capacity among patients, with logp27 decrease 309 
values ranging from 0.02 to 3.7 (Fig. 3B). Interestingly, in two patients who had the steepest 310 
decline in CD4
+
 T-cell counts over the 3 years preceding study inclusion (92.5 and 215.7 311 
cells/mm3/year), their CD8
+ 
T-cells showed no ex vivo capacity to suppress HIV-2 infection in 312 
our assay (Fig. 4A). Accordingly, we found a positive correlation between capacity of CD8
+ 
T-313 
cells to mediate HIV-2 suppression ex vivo and the patients’ CD4 T-cell counts (Fig. 4B), 314 
which supports the key role of these CD8
+ 
T-cells in suppressing HIV-2 infection and 315 
preventing disease progression. These results are in line with previous studies showing that 316 
strong CD8
+ 
T-cell mediated HIV-1 suppression ex vivo correlates with better clinical outcome 317 
(38, 44, 45), and strengthen the value of the HIV-1/2 suppression assay as a correlate of HIV 318 
control. 319 
320 
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Discussion 321 
Although the immune dynamics responsible for the slow progression of HIV-2 322 
infection has remained puzzling for years, we are gaining momentum in piecing together the 323 
precise picture of events that are responsible for this largely non-progressive HIV infection. 324 
At equivalent plasma viral loads, proviral DNA loads are very similar between HIV-1 and HIV-325 
2 infections (1, 46-48). When left unchecked by cART, the survival of HIV-2 infected patients 326 
is strongly related to both CD4
+ 
T-cell counts and plasma viral load. However, in contrast to 327 
HIV-1, HIV-2 is often controlled to undetectable plasma viral loads in the absence of cART, 328 
which most likely involves a complex immune-related mechanism.  329 
Owing to the maintenance of a strong lymphopoietic capacity, T-cell mediated 330 
immune responses appear to be better preserved in HIV-2 infection and HIC2 can sustain the 331 
robust suppression of viremia over several years or even decades of chronic infection. HIV-2-332 
specific CD8
+ 
T-cells display an early or young differentiated phenotype, potentially reflecting 333 
their potential for T-cell renewal. They also harbor particularly potent effector functions, 334 
highlighted by their exceptional capacity to suppress the virus in autologous CD4
+ 
T-cells. 335 
These CD8
+ 
T-cell characteristics are similar to those observed in HIC1 in many aspects, and 336 
are likely to be part of the cause or consequence of effective control over the virus. This 337 
robust lymphopoietic potential is not preserved or restored in the CD8
+ 
T-cells of HIV-338 
infected patients undergoing antiretroviral treatment even when initiated during primary 339 
HIV-1 infection (41), which argues more in favor of causality.  340 
Although overall, strong CD8+ T cell-mediated HIV-2 suppression is observed in HIC2 341 
patients, some heterogeneity, as in HIC1, is observed in these patients (39, 49-51). The 342 
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absent or low CD8+ T cell-mediated HIV-2 suppression in four patients may be due to several 343 
factors. First, we cannot exclude the possibility that strong CD8+ T cell viral suppression was 344 
not elicited in these individuals due to other immunodominant epitopes that were not 345 
encoded by the HIV-2 SBL virus strain used in our experiments. However, we have previously 346 
shown that suppressive CD8 T-cell activity in HIV-1 controllers remained low in some donors 347 
even when autologous virus was used (39). Alternatively, the absence of suppressive activity 348 
may be a consequence of the stringent control of viremia, resulting in the contraction of the 349 
HIV-2 specific CD8+ T cell response to a small pool of high quality memory cells that fall 350 
below the detection threshold of our assay (49, 52, 53). Moreover, we were only able to 351 
analyse the CD8+ T cell response in blood, and would not be able to measure more robust 352 
responses that were active locally in patient tissues (54). Finally, other mechanisms such as 353 
innate or humoral responses, or infection with unfit virus, may exert a greater role than the 354 
activity of CD8+ T cells in controlling viremia in these patients. 355 
The effective suppression of viral replication in HIC2 will prevent the development of 356 
chronic immune activation and further damage to the lymphopoietic system, thus allowing 357 
the maintenance of an effective CD8
+ 
T-cell immune response which provides long-term 358 
control of the virus. This equilibrium between HIV-2 and host immunity may be referred to 359 
as a virtuous cycle, in contrast to the vicious cycle in HIV-1 infection, where apart from 360 
exceptional HIC1 cases, poorly controlled viral replication results in elevated chronic immune 361 
activation. The intensity of prolonged HIV-1 replication contributes to a process of 362 
premature immune aging that exerts its toll and further weakens cellular immunity in 363 
infected individuals. 364 
 365 
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We do not yet have a complete picture to explain the benign virtuous cycle of HIV-2 366 
infection; whilst many epidemiological studies have found an association between specific 367 
HLA class I alleles and HIV-1 disease outcome, i.e. rapid or delayed progression to AIDS (11), 368 
the role of HLA polymorphism in HIV-2 is still unclear. Evidence exists that HLA-B*35 (55) and 369 
B*1503 (56) alleles are associated with HIV-2 disease progression; nevertheless several 370 
individuals bore HLA-B*35 alleles in our study, yet controlled their infection. Similarly, in the 371 
context of HIV-1 infection, HLA class I homozygosity is associated with rapid progression to 372 
AIDS (57, 58); however most of the HIC2 in our study are homozygotes. Interestingly, no HLA 373 
allele associated with control of infection has been found in HIV-2 infection. It was suggested 374 
by Yindom et al. (56) that this might be due to the fact that HIV-2 infection is easier to 375 
control compared to HIV-1, and therefore that less stringent requirements for control may 376 
not have led to the selection of “protective” epitopes that are restricted by specific HLA 377 
molecules during HIV-2 infection. Additionally, unlike the partial control exerted by CD8
+
 T 378 
cells in HIV-1 infection (59), the robust CD8
+
 T cell control of HIV-2 could limit the emergence 379 
of escape variants, and therefore abrogate the requirement for HLA Class I molecules that 380 
possess sufficient flexibility to adapt to new variants. 381 
While still hypothetical at this stage, a greater sensitivity of HIV-2, compared with 382 
HIV-1, to intracellular restriction factors may play a crucial role in constraining the initial 383 
replication of HIV-2 in CD4+ T-cells. It has been shown that HIV-2 is more susceptible to 384 
restriction by tripartite motif protein isoform 5 alpha (TRIM5a) than HIV-1 (60). 385 
Subsequently, it was found that tetherin interacts differentially with the two viruses 386 
depending on whether it is counteracted by Vpu or Env, as is the case in HIV-1 and HIV-2 387 
respectively (61, 62). This difference might reflect a different sensitivity of HIV-1 and HIV-2 388 
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to tetherin control at the cell membrane. cART-naïve HIV-2 infected patients from the ANRS 389 
CO5 HIV-2 Cohort also demonstrated high level of APOBEC3F/G editing activity in a previous 390 
study (63); however, immunovirological parameters were not found to be associated with 391 
the latter.  392 
Finally, it has been proposed that the presence of the HIV-2/SIVsmm-specific Vpx, an 393 
accessory protein that inhibits the action of SAMHD1, enhances the sensing of HIV-2 by 394 
dendritic cells, which may promote the induction of more potent CD8
+ 
T-cell responses (64). 395 
This requires further investigation, as other groups have reported that dendritic cells are 396 
refractory to HIV-2 infection, which could in turn, restrict HIV-2 replication (65, 66). Overall, 397 
an enhanced sensitivity of HIV-2 to host restriction factors may be crucial in limiting its 398 
replication initially, preventing further damage to the host immune system, providing the 399 
necessary window of opportunity for the subsequent induction and enactment of an 400 
effective T-cell response that establishes and maintains control of the virus. Once activated, 401 
this timely bottleneck would prevent the over-exertion and subsequent exhaustion of 402 
immune resources - usually related to the maintenance of the CD4 T-cell pool and the 403 
consumption of HIV-specific immune cells – together with the presence of the associated 404 
hyper inflammatory status often seen in HIV-1 infection; ultimately preserving the immune 405 
functions of the infected person. Combined together, this synergy in innate and adaptive 406 
factors may provide the necessary conditions for to establish the HIV-2 virtuous circle, and 407 
therefore exemplify a holistic mechanism for natural control of the virus. 408 
 409 
410 
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Figure Legends 670 
Figure 1. Lymphopoietic capacity of HIV-2 infected individuals. (a) Representative example 671 
of CD34 and lineage staining to identify HPC within total PBMCs from a HIV-2 infected 672 
patient (left panel) and absolute counts (right panel) of CD34
+
 Lin
-
 cells in middle aged 673 
healthy adults (HIV neg), treatment naïve viremic HIV-1 infected patients with high (HIV-1 674 
CD4>500 CD4
+
 T-cells/µl) or low (HIV-1 CD4<200 CD4
+
 T-cells/µl) CD4
+
 T cell count, HIV-1 675 
controllers (HIC1) and HIV-2 controllers (HIC2). (b) Representative example of CD117 and 676 
CD45RA staining on CD34
+
 enriched cells to identify circulating lymphoid precursors in a HIV-677 
2 infected patient (left panel) and absolute counts (right panel) of CD117
- 
CD45RA
+
 CD34
+
 678 
cells in middle aged healthy adults (HIV neg), treatment naïve viremic HIV-1 infected patients 679 
with high (HIV-1 CD4>500 CD4
+
 T-cells/µl) or low (HIV-1 CD4<200 CD4
+
 T-cells/µl) CD4
+
 T cell 680 
count, HIV-1 controllers (HIC1) and HIV-2 controllers (HIC2). (c) Representative example of 681 
CCR7 and CD45RA staining on CD8
+
 T-cells to identify naïve cells in a HIV-2 infected patient 682 
(left panel) and frequency (right panel) of naïve cells in middle aged healthy adults (HIV neg), 683 
treatment naïve viremic HIV-1 infected patients with high (HIV-1 CD4>500 CD4
+
 T-cells/µl) or 684 
low (HIV-1 CD4<200 CD4
+
 T-cells/µl), HIV-1 controllers (HIC1) and HIV-2 controllers (HIC2). 685 
(d) Correlation between sj TREC levels (sjTREC/mL) and naïve CD8
+
 T-cell counts in HIV-2 686 
controllers. (e) Correlation between the counts of recent thymic emigrants and naïve CD8
+
 T-687 
cells in HIV-2 controllers. The Mann-Whitney test was used for comparing groups. The 688 
Spearman‘s rank test was used to determine correlations. Bars indicate the median. 689 
 690 
Figure 2. Characterization of p27-specific CD8
+ 
T-cells in HIV-2 infected individuals. (a) 691 
Representative example of IFNγ secretion in CD8+ T-cells from a HIV-2 infected patient 692 
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unstimulated or upon stimulation with p27 overlapping peptides (left panel) and frequencies 693 
of IFNγ+ CD8+ T-cells in HIV-1 controllers (HIC1) and HIV-2 controllers (HIC2) upon stimulation 694 
with HIV-1 and HIV-2 peptides respectively (right panel). (b) Representative stainings of HLA-695 
B*5301 restricted p27 TPYDINQML (TL9) (left panel) or HLA-B*1401 restricted p27 696 
DRFYKSLRA (DA9) (right panel) specific CD8
+ 
T-cells from HIV-2 infected patients. (c) 697 
Representative stainings for the expression of the cell surface markers CD27, CD28, CD45RA, 698 
CCR7, CD127 and intracellular granzyme B in TL9-specific CD8+ T-cells. (d) Comparative 699 
expression of the cell surface markers CD27, CD28, CD45RA, CCR7, CD127 and intracellular 700 
granzyme B between B27 KK10-specific CD8+ T-cells from HIV-1 infected patients (open 701 
diamonds) and B53 TL9 or B14 DA9-specific CD8+ T-cells from HIV-2 infected patients (full 702 
circles). The Mann-Whitney test was used for comparing groups. Bars indicate the median. 703 
 704 
Figure 3. Ex vivo viral suppressive capacity of HIV-2 infected individuals CD8
+ 
T-cells. (a) 705 
Examples of p27 concentration in supernatant of CD4
+ 
T-cells isolated from an HIV-2 706 
controller (top) or an healthy donor (bottom), alone (red) or co-cultured with autologous 707 
CD8
+
 T-cells (blue) at different days post infection. Data are represented as Means and 708 
Standard Deviations. (b) Log p27 decrease (p27 concentration in supernatant of infected 709 
CD4
+ 
T-cells alone divided by p27 concentration in supernatant of infected CD4
+ 
T-cells co-710 
cultured in presence of autologous CD8 T-cells) in HIV-1 (open diamonds) or HIV-2 711 
controllers (black circles). Bars indicate the median. (c) p27 concentration in supernatant of 712 
CD4
+ 
T-cells isolated from 3 different HIV-2-infected individuals, alone (red columns) or co-713 
cultured with autologous CD8 T-cells (blue columns) at time of inclusion (Month 0, M0) or 12 714 
months later (M12). Histograms are represented as Means and Standard Deviations. 715 
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 716 
Figure 4. HIV-2 viral suppressive function and markers of disease progression. (a) p27 717 
concentrations in supernatant of CD4
+ 
T-cells isolated from HIV-2 infected individuals with 718 
rapidly decreasing CD4
+ 
T-cells during at least 3 years (92.5 cells/mm3/year (left) and 215.7 719 
cells/mm3/year (right)), alone (red) or co-cultured with autologous CD8 T-cells (blue) at 720 
different days post infection. Data are represented as Means and Standard Deviations. (b) 721 
Correlation of CD4
+ 
T-cell counts (cells/mm3) and log p27 decrease (p27 concentration in 722 
supernatant of infected CD4
+ 
T-cells alone divided by p27 concentration in supernatant of 723 
infected CD4
+ 
T-cells co-cultured in presence of autologous CD8 T-cells) in HIV-2-infected 724 
individuals. The Spearman‘s rank test was used to determine correlations. 725 
 726 
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Table I. Clinical attributes of the HIV-2-infected patients studied 1 
ID Gender 
Age 
(years) 
CD4 count 
(cells/µl) 
Time since 
diagnosis 
(years) 
Viral load 
(copies/mL) 
HLA A HLA B HLA C Country of Birth 
012-006 M 44 707 20.5 <40 03/23 35/53 04/04 Ivory Coast 
012-009 F 54 1,118 27.3 <100 03/74 14/15 07/08 Guinea Conakry 
012-045 F 43 858 22.7 <40 1/33 15/35 04/14 France 
012-073 M 52 891 11.3 <100 02/03 49/57 07/18 Ivory Coast 
012-084 F 50 1,776 8.8 <40 68/68 07/52 - Ghana 
012-088 M 70 502 7.4 117 02/02 27/53 02/04 Senegal 
012-101 F 34 1,212 12.5 <40 03/26 58/58 03/07 The Gambia 
013-035 F 48 859 9.2 <40 34/34 15/53 02/04 Guinea Conakry 
013-037 M 59 1,300 8.8 <40 01/29 44/57 06/16 Colombia 
013-049 F 52 604 25.6 <40 02/23 15/52 02/16 Guinea Conakry 
019-010 F 40 1,170 15.4 - 33/68 53/53 04/04 Ivory Coast 
023-008 F 41 - 5.0 <40 34/34 7/53 04/07 Ivory Coast 
028-012 F 28 827 10.2 <40 - 18/78 05/16 Guinea Conakry 
028-016 F 49 895 11.3 <40 02/68 15/51 14/16 Ivory Coast 
036-018 F 39 1,036 12.7 <100 03/03 35/53 04/04 Ivory Coast 
036-019 M 53 1,228 17.6 <40 23/23 07/14 07/08 Guinea Bissau 
045-007 F 50 - 16.2 40 33/33 53/53 04/04 Ivory Coast 
051-007 M 48 399 14.4 <40 02/29 39/44 07/16 France 
075-001 M 52 413 18.2 54 24/25 35/44 05/12 France 
082-005 M 57 1,090 23.0 <100 23/34 53/53 04/04 Ivory Coast 
 2 
 3 
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Table II. Summary of clinical attributes of the patients studied 1 
Group Gender (%female) Age (years) CD4 count (cells/µl) Viral load (copies/mL) 
HIV1-negative 51% 39 [33-47] 860 [610-1,110] NA 
HIV1+ CD4<200 30% 40 [32-48] 82 [42-136] 127,330 [3,040-543,000] 
HIV1+ CD4>500 11% 39 [31-48] 690 [560-910] 16,540 [800-6,300] 
HIV1+-controllers 53% 48 [42-51] 751 [519-953] <40 [<40-57] 
HIV2+-controllers 60% 49 [42-52] 893 [707-1,170] <40 [<40-88.5] 
Values are expressed as: median [interquartile range] 2 
 3 
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Supplementary Figure 1. Naïve T-cell count levels in HIV-2 infected individuals. 
 
(a) Correlation between naïve CD8
+
 and naïve CD4
+
 T-cell counts in HIV-2 controllers. (b) 
Correlation between the counts of recent thymic emigrants (RTE) and naïve CD4
+
 T-cells in 
HIV-2 controllers. The Spearman‘s rank test was used to determine correlations. 
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Supplementary Figure 2. Polyfunctional potential of HIV-2 p27-specific CD8
+ 
T-cells. 
 
(a) Representative examples of MIP-1β, CD107a, TNFα and IFNγ secretion in CD8+ T-cells 
from a HIV-2 infected patient upon stimulation with p27 overlapping peptides. (b) 
Frequencies of CD8
+
 T-cells secreting IFNγ, MIP-1β, CD107a or TNFα in HIV-2 infected 
patients upon stimulation with p27 overlapping peptides respectively. Data are normalized 
mean percentages from nine patients 
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Supplementary Figure 3. Expression of T-BET and EOMES in HIV-2 p27-specific CD8
+ 
T-cells. 
 
(a) Representative stainings for the intracellular expression of the transcription factors T-BET 
and EOMES in B53-TL9-specific CD8
+
 T-cells. (b) Expression of the transcription factors T-BET 
and EOMES in B53 TL9 or B14 DA9-specific CD8+ T-cells from HIV-2 infected patients. 
